{"nctId":"NCT04341116","briefTitle":"Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)","startDateStruct":{"date":"2020-04-11","type":"ACTUAL"},"conditions":["Coronavirus Disease 2019 COVID-19"],"count":149,"armGroups":[{"label":"TJ003234 Medium Dose","type":"EXPERIMENTAL","interventionNames":["Drug: TJ003234"]},{"label":"TJ003234 Low Dose","type":"EXPERIMENTAL","interventionNames":["Drug: TJ003234"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"TJ003234 High Dose","type":"EXPERIMENTAL","interventionNames":["Drug: TJ003234"]}],"interventions":[{"name":"TJ003234","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age: 18 years or older (including 18 years); male or female\n* Laboratory-confirmed SARS-CoV-2 or COVID-19 infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay.\n* Bilateral lung infection confirmed by imaging.\n* Severe disease that meets one of the following conditions: (i) At rest, finger blood oxygen saturation ≤ 93% or PaO2/FiO2 ≤ 300 mmHg; (ii) Requiring non-invasive or invasive mechanical ventilation; OR (iii) Requiring high flow oxygen ≥ 15L/min\n* Hospitalized for no more than 5 calendar days at the time of screening\n\nExclusion Criteria:\n\n* Any previous and/or current clinically significant disease or condition that has not been stable within 3 months prior to enrollment, or acute illness, planned medical/ surgical procedure, or any trauma that occurred within 2 weeks prior to enrollment.\n* Chronic obstructive pulmonary disease (COPD) patients requiring inhaled corticosteroid, long-acting beta-adrenergic agonists, long-acting anticholinergics, or long-term oxygen therapy (Part 1 only).\n* Pulmonary interstitial disease, pulmonary alveolar proteinosis, and pulmonary granulomatosis.\n* Cardiovascular event in the 3 months prior to study drug administration: acute myocardial infarction or unstable angina pectoris, severe arrhythmia (multiple sources of frequent ventricular premature beat, ventricular tachycardia and ventricular fibrillation); New York Heart Association Classification (NYHA): Class III-Class IV.\n* Blood system disorders or routine blood analysis test abnormalities: Hemoglobin \\< 8 g/dL; Absolute neutrophil count (ANC) \\<1500 × 109/L; Platelets \\< 50 × 109/L.\n* Dependence on glucocorticoid treatment equivalent to methylprednisolone 2 mg/kg/ day or more or long-term use of anti-rejection or immunomodulatory drugs.\n* Subjects that have been on invasive mechanical ventilation for ≥120 hours at the time of dosing\n* Subjects that require ECMO.\n* Pregnant or breastfeeding females.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects Alive and Free of Mechanical Ventilation Among Subjects Who Are Free of Mechanical Ventilation at Baseline","description":"Free of mechanical ventilation was defined as proportion of subjects who scores 1 to 5 in the following 8-category ordinal scale.\n\n8, death; 7, ventilation in addition to extracorporeal membrane oxygen (ECMO), continuous renal replacement therapy (CRRT) or pressors; 6, intubation and mechanical ventilation; 5, non-invasive mechanical ventilation (NIV) or high-flow oxygen; 4, hospitalization with oxygen by mask or nasal prongs; 3. Hospitalization without oxygen supplementation; 2, limitation of activities, discharge from hospital; and 1, no limitation of activities, discharge from hospital.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"56","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Recovery by Day 14","description":"Sustained recovery in clinical status was defined as patients who have hospitalization without oxygen supplement or discharge from hospital.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"47","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Recovered on Day 30","description":"Sustained recovery in clinical status was defined as patients who have hospitalization without oxygen supplement or discharge from hospital.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"56","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"All-cause Mortality Rate by Day 30","description":"The percentage of subjects who deceased by any cause.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Recovery Among Subjects Alive by Day 30","description":"Time to sustained recovery","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"6.5","spread":null},{"groupId":"OG004","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Length of Hospitalization","description":"Duration of hospitalization","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"9.5","spread":null},{"groupId":"OG004","value":"11","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":8},"commonTop":[]}}}